Hansa Biopharma AB (publ) (LON: 0RC7)

Market Cap	158.75M
Revenue (ttm)	13.93M
Net Income (ttm)	-48.17M
Shares Out	n/a
EPS (ttm)	-0.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,386
Average Volume	4,097
Open	88.40
Previous Close	104.50
Day's Range	84.70 - 88.40
52-Week Range	45.06 - 105.70
Beta	1.46
RSI	42.55
Earnings Date	Feb 6, 2025

About Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseas...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 135
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RC7

Financial Performance

In 2023, Hansa Biopharma AB's revenue was 134.09 million, a decrease of -13.22% compared to the previous year's 154.53 million. Losses were -831.72 million, 36.1% more than in 2022.

Financial numbers in SEK